Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

Clinical trial NCT04249362 · COMPLETED

Trial details

NCT number: NCT04249362
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2020-11-26
Primary completion: 2023-03-30
Enrollment: 102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.